期刊文献+

Galectin-3在脑膜瘤中的表达及其与术后复发的关系

The relationship between Galectin-3 expression in Meningioma and postoperative recurrence
下载PDF
导出
摘要 目的研究Galectin-3在脑膜瘤中的表达水平及其与脑膜瘤术后复发的关系。方法收集行Simpson Ⅰ级切除治疗并经至少5年随访的60例脑膜瘤患者的临床资料,采用SP免疫组化法,检测病理标本中Galectin-3蛋白表达水平;结合患者的临床资料,对脑膜瘤病理标本的Galectin-3蛋白表达进行统计学分析。结果 Galectin-3在不同级别的脑膜瘤中表达具有统计学意义(P<0.05),Galectin-3在恶性脑膜瘤及非典型性脑膜瘤中的表达明显高于良性脑膜瘤;Galectin-3的表达在良性复发组明显高于良性未复发组(P<0.05)。结论 Galectin-3蛋白的表达水平与脑膜瘤病理分型有一定关系,其表达水平随着脑膜瘤WHO病理分级的增加而增高;Galectin-3表达情况可作为判断良性脑膜瘤有无复发的辅助指标之一。 Objective To study the relation between the expression of Galectin -3 and meningioma postoperative recurrence. Methods Sixty patients were collected in this study who applied Simpson level - I resection, pathologically confirmed as meningioma, and they were followed up for at least 5 years. Then Galectin - 3 protein was determined in pathological tissues by immunohistochemical method, and differences of Galectin - 3 expression were observed in different categories. Results The expression of Galectin - 3 protein in different pathological grade of meningiomas were significant differences ( P 〈 0.05 ), the expression of Galectin - 3 protein in malignant meningiomas and atypical meningiomas was significantly higher than that in benign meningiomas ( P 〈 0.05 ). The expression of Galectin - 3 protein in recurrent benign meningiomas group were significantly higher than that in the non recurrent benign meningiomas group ( P 〈 0.05). Conclusion The expression of Galectin - 3 protein in meningioma pathology and tumor recurrence has a certain relationship, which is higher with the increase of meningioma WHO pathological grade. The expression of Galectin - 3 can be used as one of auxiliary indicators which can be used to determine whether the possibility of benign meningiomas'recurrence.
出处 《宁夏医学杂志》 CAS 2011年第3期212-214,F0002,共4页 Ningxia Medical Journal
基金 宁夏科技攻关项目(NK2010)
关键词 脑膜瘤 复发 GALECTIN-3 Meningioma recurrence Galectin - 3
  • 相关文献

参考文献2

二级参考文献53

  • 1Michael AH, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev, 2004, 4 : 45- 60.
  • 2Jerka D, Sanja D, Mirna F. Galectin-3 : An open-ended story. Biochimica et Biophysica Acta, 2006, 1760 : 616 - 635.
  • 3Nanqia-Mavker P, Conklin J, Hogan V, et al. Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents. Trends Mol Med, 2002, 8 : 187-192.
  • 4Raz A. Lectin-like activities associated with human and murine neoplastic cells. Cancer Res, 1981, 41 : 3642.
  • 5Yang ZM,Wu XT,He T. Galectin-3 and Tumor Metastasis. Chinese J Gener Sur Basic Clin, 2005,12 : 10- 313.
  • 6Acosta-Rodriguez EV, Montes CL, Motran CC, et al. Galectin-3 mediates IL--4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J Immunol, 2004, 172 : 493 - 502.
  • 7Liu L, Takashi S, Nobuya S, et al. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signaling. Biochem J, 2004.380 : 31 -41.
  • 8Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol, 2000,165 : 2156-2164.
  • 9Nangia-Makker P, Honjo Y, Sarvis R, et al. Galeetin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol, 2000, 156 : 899- 909.
  • 10Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer. Semin Cancer Biol, 2000, 10 : 407.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部